Journal of oncology research and therapy最新文献

{"title":"Thermal Camera Application in Gynecological Oncology: Feasibility Study of a Novel Technology","authors":"","doi":"10.29011/2574-710x.10203","DOIUrl":"https://doi.org/10.29011/2574-710x.10203","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"6 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140241754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Genotype of the ABO Blood Group System among Saudi Population","authors":"","doi":"10.29011/2574-710x.10201","DOIUrl":"https://doi.org/10.29011/2574-710x.10201","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140415094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Young’s Moduli of Human Lung Parenchyma and Tumours","authors":"","doi":"10.29011/2574-710x.10198","DOIUrl":"https://doi.org/10.29011/2574-710x.10198","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"86 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139810655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Young’s Moduli of Human Lung Parenchyma and Tumours","authors":"","doi":"10.29011/2574-710x.10198","DOIUrl":"https://doi.org/10.29011/2574-710x.10198","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"87 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139870548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Angiosarcoma Case Report","authors":"","doi":"10.29011/2574-710x.10196","DOIUrl":"https://doi.org/10.29011/2574-710x.10196","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139871368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Angiosarcoma Case Report","authors":"","doi":"10.29011/2574-710x.10196","DOIUrl":"https://doi.org/10.29011/2574-710x.10196","url":null,"abstract":"","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"9 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139811037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Primary Malignant Melanoma of the Lung with BRAF V600E Mutation and Distinctive Bronchoscopic Features","authors":"Hiroki Nishimura, Yasutaka Kawai, Yumi Morinaga, Mikio Watanabe, Teruki Yanagi, Takayuki Kiuchi, Satoshi Tanaka, Yasuyuki Ikezawa","doi":"10.29011/2574-710x.10197","DOIUrl":"https://doi.org/10.29011/2574-710x.10197","url":null,"abstract":"A 79-year-old male patient was referred to our healthcare facility because of an abnormal CT shadow detected during follow-up of prostatectomy. The nodules revealed a tendency of increasing in size, and primary lung cancer was suspected. The patient underwent a right lower lobectomy and mediastinal","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"54 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140492680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers.","authors":"Ahmad A Tarhini, Dale Hedges, Aik Choon Tan, Paulo Rodriguez, Vineeth Sukrithan, Aakrosh Ratan, Mar-Tin D McCarter, John Carpten, Howard Colman, Alexandra P Ikeguchi, Igor Puzanov, Susanne M Arnold, Michelle L Churchman, Patrick Hwu, Jose R Conejo-Garcia, William S Dalton, George J Weiner, Islam Eljilany","doi":"10.29011/2574-710x.10224","DOIUrl":"10.29011/2574-710x.10224","url":null,"abstract":"<p><strong>Purpose: </strong>The promise of immune checkpoint inhibitor (ICI) therapy underlines the importance of comprehensively investigating the rationale for combinations with diverse immune modulators across different cancer types. Given the progress made with PD1 blockade to date, we examined mRNA co-expression levels of PD-1 with 13 immune checkpoints, including co-inhibitory receptors (LAG3, CTLA4, PD-L1, TIGIT, TIM3, VISTA, BTLA) and co-stimulatory molecules (CD28, OX40, GITR, CD137, CD27, HVEM), using RNA-Seq by Expectation-Maximization (RSEM).</p><p><strong>Methods: </strong>We analyzed real-world clinical and transcriptomic data from the Total Cancer Care Protocol (NCT03977402) and Avatar^® project of patients with cancer treated within the Oncology Research Information Exchange Network (ORIEN) network. Using anti-PD1 as a backbone, we intended to investigate the rationale for combinations in different cancers. Pearson's R coefficients and associated P-values were calculated using SciPy 1.7.0.</p><p><strong>Results: </strong>The co-expression of PD1 with 13 immune checkpoints and PD-L1 varies across selected malignancies included. In cutaneous melanoma, PD1 expression correlated significantly with four co-inhibitory receptors (LAG3, TIM3, TIGIT, VISTA) and one co-stimulatory molecule (CD137). In urothelial carcinoma, PD1 expression significantly correlated with four co-inhibitory (TIGIT, CTLA4, LAG3, VISTA) and four co-stimulatory (OX40, CD27, CD137, HVEM) molecules. In pancreatic adenocarcinoma, only CD28 showed a significant correlation with PD1 expression. No significant correlations with PD1 expression were found in the ovarian cancer cohort. Notably, melanoma and urothelial carcinoma exhibited a dominant co-expression of co-inhibitory molecules with PD1, indicative of exhausted T cells, in contrast to the co-stimulatory molecule dominance in ovarian and pancreatic cancers, suggesting less differentiated T cells.</p><p><strong>Conclusions: </strong>Our findings highlight the potential for diverse combination strategies in immunotherapy, particularly with PD1 blockade, across various cancers.</p>","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"9 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143627055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Ceramide and Sphingolipid Metabolism in Cancer Therapeutics.","authors":"Andrea L Cote, Kyla S Jarvis, Brian M Barth","doi":"10.29011/2574-710x.10257","DOIUrl":"https://doi.org/10.29011/2574-710x.10257","url":null,"abstract":"<p><p>Sphingolipids are a class of bioactive lipids which are highly involved in cellular functions such as signaling, membrane composition, and determining cell fate. The metabolism of these lipids plays important roles in the development and progression of many diseases such as cancer. The role of sphingolipid metabolism in cancer overall is not yet fully understood. However, key sphingolipids such as sphingosine-1-phosphate (S1P) and ceramide have been shown to be influential on the death or survival of cancer cells. S1P is known to exert pro-survival signaling effects when expressed at higher levels in cells. Ceramide, on the other hand, has been established as a pro-death lipid, regulating apoptosis, cell cycle arrest, autophagy, and mitophagy. Cancer cells are typically characterized by an increased ratio in S1P to ceramide, thus granting the survival of the cancer. This ceramide/S1P biostat is the target of many new therapeutics which aim to increase ceramide levels in cancer cells. Additionally, many previously established drugs have been rediscovered for their unexpected ability to perturb sphingolipid metabolism. This review serves to summarize the current use of ceramide and sphingolipid metabolism-related therapies for the treatment of many cancers.</p>","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"9 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Boron Neutron Capture Therapy Using Polymalic Acid Derived Nano-Boron to Treat Glioblastoma.","authors":"R Patil, T Sun, O Chepurna, M Khoobchandani, S Rudensky, E Holler, J Y Ljubimova, K L Black","doi":"10.29011/2574-710x.10226","DOIUrl":"10.29011/2574-710x.10226","url":null,"abstract":"<p><p>Despite extensive efforts, glioblastoma multiforme (GBM), the most malignant brain cancer, continues to pose significant challenges to effective treatment, with limited progress in patient survival over the last three decades. This study addresses shortcomings of conventional therapies, particularly radiotherapy (RT), which faces limitations due to radio-resistance and toxic radiation doses. Boron neutron capture therapy (BNCT) is a promising alternative, delivering targeted radiation to tumor cells with minimal damage to healthy tissue. However, the key challenge lies in achieving sufficient boron uptake selectively in tumor cells. We have developed a novel nanomedicine-based approach, utilizing polymalic acid (PMLA) as a delivery vehicle, carrying multiple boron-10 molecules per nanoconjugate to increase the intracellular concentration of boron-10 for effective boron neutron capture therapy. Our novel nanodrug (Nano-Boron) incorporates isotopically enriched 4-boronophenylalanine (BPA) as a source of boron-10 and Angiopep-2 (AP2) peptide for blood-brain barrier penetration and tumor targeting. The PMLA platform allows for the attachment of a large quantity of boron-10, enhancing the intracellular boron concentration and, consequently, the efficacy of BNCT. This innovative approach holds the potential to address the unmet clinical need in GBM treatment and improve patient survival and quality of life.</p>","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"9 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}